CL2007003101A1 - Inhibidor de la agregacion de inmunoglobulinas; acido nucleico de dicho inhibidor; vector y celula huesped con dicho acido nucleico; procedimiento para hacer dicho inhibidor; formulacion farmaceutica que lo comprende; uso del inhibidor para tratar en - Google Patents

Inhibidor de la agregacion de inmunoglobulinas; acido nucleico de dicho inhibidor; vector y celula huesped con dicho acido nucleico; procedimiento para hacer dicho inhibidor; formulacion farmaceutica que lo comprende; uso del inhibidor para tratar en

Info

Publication number
CL2007003101A1
CL2007003101A1 CL200703101A CL2007003101A CL2007003101A1 CL 2007003101 A1 CL2007003101 A1 CL 2007003101A1 CL 200703101 A CL200703101 A CL 200703101A CL 2007003101 A CL2007003101 A CL 2007003101A CL 2007003101 A1 CL2007003101 A1 CL 2007003101A1
Authority
CL
Chile
Prior art keywords
inhibitor
nucleic acid
immunoglobulins
understands
aggregation
Prior art date
Application number
CL200703101A
Other languages
English (en)
Inventor
T De Wildt Rudolf James Leo M
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2006/004559 external-priority patent/WO2007066106A1/en
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of CL2007003101A1 publication Critical patent/CL2007003101A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL200703101A 2006-10-30 2007-10-26 Inhibidor de la agregacion de inmunoglobulinas; acido nucleico de dicho inhibidor; vector y celula huesped con dicho acido nucleico; procedimiento para hacer dicho inhibidor; formulacion farmaceutica que lo comprende; uso del inhibidor para tratar en CL2007003101A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0621513.1A GB0621513D0 (en) 2006-10-30 2006-10-30 Novel polypeptides and uses thereof
PCT/GB2006/004559 WO2007066106A1 (en) 2005-12-06 2006-12-05 Ligands that have binding specificity for egfr and/or vegf and methods of use therefor

Publications (1)

Publication Number Publication Date
CL2007003101A1 true CL2007003101A1 (es) 2008-06-06

Family

ID=37546170

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200703101A CL2007003101A1 (es) 2006-10-30 2007-10-26 Inhibidor de la agregacion de inmunoglobulinas; acido nucleico de dicho inhibidor; vector y celula huesped con dicho acido nucleico; procedimiento para hacer dicho inhibidor; formulacion farmaceutica que lo comprende; uso del inhibidor para tratar en

Country Status (10)

Country Link
US (1) US8236931B2 (es)
EP (1) EP2079761A2 (es)
JP (1) JP2010508016A (es)
AR (1) AR063416A1 (es)
CA (1) CA2667141A1 (es)
CL (1) CL2007003101A1 (es)
GB (1) GB0621513D0 (es)
PE (1) PE20081141A1 (es)
TW (1) TW200825103A (es)
WO (1) WO2008052933A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
KR20100132535A (ko) * 2008-03-31 2010-12-17 글락소 그룹 리미티드 약물 융합체 및 컨주게이트
SG173488A1 (en) 2009-02-19 2011-09-29 Glaxo Group Ltd Improved anti-serum albumin binding variants
CA2767752C (en) 2009-02-19 2020-07-07 Glaxo Group Limited Improved anti-serum albumin binding variants
US10822396B2 (en) 2009-12-15 2020-11-03 MuHyeon CHOE Repeat-chain for the production of dimer, multimer, multimer complex and super-complex
US20120259099A1 (en) * 2009-12-15 2012-10-11 MuHyeon CHOE Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an adherend of a type specifically adhering to monomers
CN101942022B (zh) * 2010-07-29 2013-07-24 华东理工大学 抗人表皮生长因子受体单链抗体-铁蛋白重链亚基蛋白、构建方法及其用途
US20140220017A1 (en) 2011-09-23 2014-08-07 Universitat Stuttgart Serum half-life extension using igbd
EP3207064A1 (en) 2014-10-17 2017-08-23 The University of Chicago Methods and compostions involving protein g variants
ES2973885T3 (es) * 2015-07-09 2024-06-24 Genmab As Anticuerpos biespecíficos y multiespecíficos y método para aislarlos
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459662B (sv) 1986-03-21 1989-07-24 Pharmacia Ab Hybrid-dna-molekyl som kodar foer ett protein med samma igg specificitet som protein g, plasmid innehaallande densamma samt foerfarande foer framstaellning av proteinet
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5643872A (en) 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
FI940732A7 (fi) * 1991-08-28 1994-04-28 Nichols Inst Diagnostics Ihmisen tyroidiperoksidaasille spesifiset autovasta-aineet
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6008058A (en) 1993-06-18 1999-12-28 University Of Louisville Cyclic peptide mixtures via side chain or backbone attachment and solid phase synthesis
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
GB9614033D0 (en) 1996-07-04 1996-09-04 Univ Manchester Modified protein G and fragments thereof
CA2292415A1 (en) 1997-06-20 1998-12-30 Innogenetics N.V. B7-binding molecules for treating immune diseases
BR9813276A (pt) 1997-10-27 2000-08-22 Unilever Nv Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
WO1999037681A2 (en) 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments
AU2003262458B2 (en) * 1998-05-21 2008-06-19 University Of Tennessee Research Foundation Methods for amyloid removal using anti-amyloid antibodies
EP1114161B1 (en) 1998-09-14 2004-03-03 Affitech As Immunoglobulin binding protein
EP1002861A1 (en) 1998-10-26 2000-05-24 Unilever Plc Antigen-binding proteins comprising a linker which confers restricted conformational flexibility
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
DE60013767T3 (de) 1999-01-19 2009-07-09 Unilever N.V. Verfahren zur herstellung von antikörperfragmenten
WO2000065067A2 (en) 1999-04-23 2000-11-02 University Of Washington Prostate-specific polynucleotides, polypeptides and their methods of use
CA2372198A1 (en) 1999-05-14 2000-11-23 Medical Research Council Protein scaffold and its use to multimerise monomeric polypeptides
AU1859201A (en) 1999-11-29 2001-06-12 Unilever Plc Immobilisation of proteins
ES2324280T3 (es) 2000-03-14 2009-08-04 Unilever N.V. Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos.
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
DE10160133A1 (de) 2001-12-07 2003-06-26 Transmit Technologietransfer Verwendung von koagulationsaktivem Antithrombin III zur Therapie von Angiogenese-abhängigen Erkrankungen
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
AU2003251238A1 (en) 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
CA2505316C (en) 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
WO2005044858A1 (en) 2003-11-07 2005-05-19 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
US6683132B1 (en) 2002-12-19 2004-01-27 Eastman Chemical Company Self-crosslinking aqueous acetoacetate-functionalized sulfonated alkyd systems
AU2003290330A1 (en) 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
EP1587838B1 (en) 2003-01-10 2015-04-15 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
US20090005257A1 (en) 2003-05-14 2009-01-01 Jespers Laurent S Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
CN1845938B (zh) 2003-06-30 2010-05-26 杜门蒂斯有限公司 多肽
GB0323238D0 (en) 2003-10-03 2003-11-05 Domantis Ltd Synthetic LG binding domains of protein L
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
KR20060120161A (ko) * 2003-11-28 2006-11-24 아스트라제네카 아베 항체
CA2588892A1 (en) * 2004-12-02 2006-06-08 Dormantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
WO2006076640A1 (en) 2005-01-14 2006-07-20 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize hepatitis b virus
CA2596925C (en) * 2005-02-08 2017-07-04 Km Biologics Co., Ltd. Method for improving expression level and stability of antibody
JP2009518024A (ja) * 2005-12-06 2009-05-07 ドマンティス リミテッド Ｅｇｆｒおよび／またはｖｅｇｆに対して結合特異性を有するリガンドおよびその使用法

Also Published As

Publication number Publication date
WO2008052933A3 (en) 2008-11-13
AR063416A1 (es) 2009-01-28
TW200825103A (en) 2008-06-16
CA2667141A1 (en) 2008-05-08
JP2010508016A (ja) 2010-03-18
WO2008052933A2 (en) 2008-05-08
US20100047237A1 (en) 2010-02-25
PE20081141A1 (es) 2008-09-16
GB0621513D0 (en) 2006-12-06
EP2079761A2 (en) 2009-07-22
US8236931B2 (en) 2012-08-07

Similar Documents

Publication Publication Date Title
CL2007003101A1 (es) Inhibidor de la agregacion de inmunoglobulinas; acido nucleico de dicho inhibidor; vector y celula huesped con dicho acido nucleico; procedimiento para hacer dicho inhibidor; formulacion farmaceutica que lo comprende; uso del inhibidor para tratar en
CL2007003807A1 (es) Anticuerpos humanos anti-cd44 o fragmentos de los mismos; acidos nucleicos que los codifican; vector y celula huesped que los comprende; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar los sintomas de trastornos mediado
CL2008001334A1 (es) Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
CL2008001129A1 (es) Variente de asparraginasa; secuencia de acido nucleico que la codifica; construccion de acidos nucleicos; vector y celula huesped; metodo para producir asparraginasa; composicion que comprende la variante; uso de la variante de asparraginasa; proceso
CL2008000857A1 (es) Acido ribonucleico de doble cadena para inhibir la expresion de un gen e6ap humano en una celula; vector y celula; composicion farmaceutica que lo comprende; y su uso para tratar trastornos asociados con el virus de papiloma humano.
CL2008000839A1 (es) Anticuerpo anti-ige/m1'; acido nucleico que lo codifica; vector y celula huesped; proceso de produccion; composicion que comprende al anticuerpo; y su uso para tratar trastornos mediados por ige.
BRPI0913063A2 (pt) Compostos acilaminoácidos e preparações de alimentos que contém os mesmos
PT2849758T (pt) Composições que compreendem o ácido zoledrónico ou compostos relacionados para o alívio da dor inflamatória e estados relacionados
HN2012002664A (es) Compuestos, composiciones de tioacetato y metodos de uso
CL2007001488A1 (es) Anticuerpo humano o humanizado anti-integrina alfa5beta1; acido nucleico que lo codifica; vector y celula huesped que lo comprenden; procedimiento de produccion; composicion farmaceutica que lo comprende; y su uso para prevenir o tratar trastornos asociados con la integrina.
CL2014002348A1 (es) Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado.
CL2014001888A1 (es) Anticuerpo aislado que se une a la proteina 5 relacionada con el receptor de lipoproteina de baja densidad (lrp5); acido nucleico que lo codifica; celula huesped; metodo de produccion; formulaciom farmaceutica que lo comprende; y su uso para tratar retinopatías.
CL2007003623A1 (es) Proteina de enlace multivalente monocatenaria con funcion efectora; acido nucleico que la codifica; vector y celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y metodo para tratar trastornos proliferativos.
CL2016001653A1 (es) Composición combinada de bromuro de glicopirronio y formoterol en solución estable presurizada para aerosol
AR071242A1 (es) Anticuerpos anti-cd37
BR112016002583A2 (pt) composições, métodos e aparelhos para uso com materiais ativáveis por energia
BR112013015467A2 (pt) composição cosmética na forma de uma emulsão óle-em-água e processo não-terapêutico para tratar as matérias queratínicas
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
CO2017000220A2 (es) Moléculas que tienen cierta utilidad pesticida, intermedios, composiciones y procesos relacionados con las mismas
CL2014000948A1 (es) Profarmaco de adrenomedulina basado en polietilenglicol; procedimiento de preparacion; composicion farmaceutica que lo comprende; y su uso para tratar y/o prevenir trastornos cardiovasculares, edematosos y/o inflamatorios.
CL2008000820A1 (es) Anticuerpo aislado o fragmentos funcionales con capacidad para neutralizar cepas hiv; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir un anticuerpo; uso del anticuerpo para el tratamie
CL2012002415A1 (es) Anticuerpo monoclonal aislado que se une al inhibidor de la via del factor tisular humano (tfpi); composicion farmacéutica que comprende dicho anticuerpo; procedimientos para tratar deficiencias o defectos genéticos o adquiridos en la coagulación; molecula de acido nucleico que codifica el anticuerpo; vector y célula huesped.
CL2007002989A1 (es) Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para el diagnostico de enfermedades relacionadas con notch3.
BR112013014189A2 (pt) composição farmacêutica que compreende transcinamaldeíco e o uso da mesma no tratamento de infecções
BR112015008389A2 (pt) compostos úteis na síntese de compostos de benzamida